NO20050300L - Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav - Google Patents
Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse deravInfo
- Publication number
- NO20050300L NO20050300L NO20050300A NO20050300A NO20050300L NO 20050300 L NO20050300 L NO 20050300L NO 20050300 A NO20050300 A NO 20050300A NO 20050300 A NO20050300 A NO 20050300A NO 20050300 L NO20050300 L NO 20050300L
- Authority
- NO
- Norway
- Prior art keywords
- adrenergic receptor
- receptor antagonists
- alpha
- stabilized formulations
- stable liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38620302P | 2002-06-20 | 2002-06-20 | |
| US41104902P | 2002-09-17 | 2002-09-17 | |
| US42115202P | 2002-10-24 | 2002-10-24 | |
| US47392003P | 2003-05-29 | 2003-05-29 | |
| PCT/US2003/019440 WO2004000219A2 (en) | 2002-06-20 | 2003-06-20 | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050300L true NO20050300L (no) | 2005-03-04 |
Family
ID=30003979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050300A NO20050300L (no) | 2002-06-20 | 2005-01-19 | Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1539170B1 (es) |
| JP (2) | JP4787977B2 (es) |
| AU (1) | AU2003247568B2 (es) |
| BR (2) | BRPI0311965B1 (es) |
| CA (1) | CA2489526C (es) |
| HK (1) | HK1079444A1 (es) |
| IL (1) | IL165599A (es) |
| MX (1) | MXPA04012507A (es) |
| NO (1) | NO20050300L (es) |
| WO (1) | WO2004000219A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2888699A1 (fr) | 2005-07-13 | 2007-01-19 | France Telecom | Dispositif de codage/decodage hierachique |
| FR2897742A1 (fr) | 2006-02-17 | 2007-08-24 | France Telecom | Codage/decodage perfectionnes de signaux numeriques, en particulier en quantification vectorielle avec codes a permutation |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| CA2899339C (en) * | 2013-02-01 | 2021-07-06 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| AU2014212275B2 (en) * | 2013-02-01 | 2018-09-06 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| UY35988A (es) | 2014-02-27 | 2015-09-30 | Sint Sa | Proceso para la producción de una solución inyectable de noradrenalina de baja concentración |
| CA3051467C (en) | 2017-01-30 | 2022-11-29 | Nevakar, Inc | Norepinephrine compositions and methods therefor |
| WO2020168213A1 (en) * | 2019-02-15 | 2020-08-20 | Massachusetts Institute Of Technology | Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents |
| CN115368310A (zh) * | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659714A (en) | 1984-03-27 | 1987-04-21 | Dentsply, Ltd. | Anesthetic methods for mammals |
| US4938970A (en) | 1987-02-06 | 1990-07-03 | Hustead Robert E | Painless electrolyte solutions |
| US5447912A (en) * | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US6387052B1 (en) | 1991-01-29 | 2002-05-14 | Edwards Lifesciences Corporation | Thermodilution catheter having a safe, flexible heating element |
| EP0691124A1 (en) | 1994-07-07 | 1996-01-10 | Sara Lee/DE N.V. | Mouth care products |
| US6331291B1 (en) | 1996-05-30 | 2001-12-18 | William R. Glace | Dentifrice gel/paste compositions |
| US5908612A (en) | 1996-12-31 | 1999-06-01 | Basf Corporation | Oral care compositions comprising liquid polyoxyalkylene compounds as solubilizers/gelling agents |
| FR2768620B1 (fr) | 1997-09-22 | 2000-05-05 | Rhodia Chimie Sa | Formulation buccodentaire comprenant des nanofibrilles de cellulose essentiellement amorphes |
| EP1058533B1 (en) | 1998-03-06 | 2002-02-06 | Fmc Corporation | High moisture toothpaste |
| US6187293B1 (en) | 1998-04-27 | 2001-02-13 | Fmc Corporation | Process for making toothpaste using low levels of carrageenan |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| DE60126265T2 (de) * | 2000-05-12 | 2007-10-31 | Novalar Pharmaceuticals, Inc. | Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung |
-
2003
- 2003-06-20 EP EP03761160.5A patent/EP1539170B1/en not_active Expired - Lifetime
- 2003-06-20 CA CA2489526A patent/CA2489526C/en not_active Expired - Lifetime
- 2003-06-20 AU AU2003247568A patent/AU2003247568B2/en not_active Ceased
- 2003-06-20 JP JP2004530955A patent/JP4787977B2/ja not_active Expired - Fee Related
- 2003-06-20 WO PCT/US2003/019440 patent/WO2004000219A2/en active Application Filing
- 2003-06-20 MX MXPA04012507A patent/MXPA04012507A/es active IP Right Grant
- 2003-06-20 BR BRPI0311965-3A patent/BRPI0311965B1/pt unknown
- 2003-06-20 BR BR0311965-3A patent/BR0311965A/pt not_active IP Right Cessation
-
2004
- 2004-12-07 IL IL165599A patent/IL165599A/en not_active IP Right Cessation
-
2005
- 2005-01-19 NO NO20050300A patent/NO20050300L/no not_active Application Discontinuation
- 2005-12-15 HK HK05111618.4A patent/HK1079444A1/xx not_active IP Right Cessation
-
2010
- 2010-08-11 JP JP2010180122A patent/JP2010280702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1539170B1 (en) | 2014-08-13 |
| AU2003247568A1 (en) | 2004-01-06 |
| WO2004000219A2 (en) | 2003-12-31 |
| EP1539170A4 (en) | 2011-01-05 |
| IL165599A0 (en) | 2006-01-15 |
| BRPI0311965B1 (pt) | 2018-04-24 |
| WO2004000219A3 (en) | 2004-03-11 |
| JP2005533869A (ja) | 2005-11-10 |
| BR0311965A (pt) | 2005-03-29 |
| AU2003247568B2 (en) | 2008-03-06 |
| HK1079444A1 (en) | 2006-04-07 |
| CA2489526C (en) | 2012-03-20 |
| JP2010280702A (ja) | 2010-12-16 |
| MXPA04012507A (es) | 2005-06-08 |
| EP1539170A2 (en) | 2005-06-15 |
| JP4787977B2 (ja) | 2011-10-05 |
| CA2489526A1 (en) | 2003-12-31 |
| IL165599A (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050300L (no) | Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav | |
| DK1280531T3 (da) | Formulering bestående af phentolaminmesylat og anvendelse heraf | |
| DE60236541D1 (de) | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
| RS50814B (sr) | Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena | |
| SE8804629D0 (sv) | New therapeutically active compounds | |
| CL2009001278A1 (es) | Compuestos biciclicos, derivados de 1-(4-pipridinil)-1,3-dihidro-2h-indol-2-ona sustituidos, analogos de nociceptina; composicion farmaceutica; y su uso en el tratamiento del dolor (div. sol. 2103-03) | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| DE60328974D1 (de) | (+)-2-ä1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylü-4-acetylaminoisoindolin-1,3-dion zur verwendung in der behandlung von psoriasis durch orale verabreichung | |
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
| AR021055A1 (es) | Derivados de pirazolopiridina | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| AR026916A1 (es) | Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales | |
| ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
| RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
| NO20022525D0 (no) | Farmasöytiske formuleringer inneholdende zolmitriptan | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| IS5401A (is) | Samsetning mónóamínoxídasa hemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun | |
| NO20004931L (no) | Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling | |
| BR0314844A (pt) | Novo composto | |
| SE8804628D0 (sv) | New compounds | |
| BR0314843A (pt) | Novo composto | |
| CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |